Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma

Por Regan, Paul L., Jacobs, Joshua, Wang, Gerald, Torres, Jaime, Edo, Robby, Friedmann, Jennifer, Tang, Xao X.
Publicado em 2011

Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)

Por Lapointe, Réjean, Jamal, Rahima, van Kempen, Leon, Thebault, Pamela, Belanger, Karl, Friedmann, Jennifer, Ayoub, Jean-Pierre, Cocolakis, Eftihia, Kazemi, Shirin, Dionne, Jeanne, Lambert, Caroline, Le, Huy, Grange, Cecile, Cailhier, Jean-Francois, Spatz, Alan, Miller, Wilson
Publicado no J Immunother Cancer (2015)

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Por Jamal, Rahima, Lapointe, Réjean, Cocolakis, Eftihia, Thébault, Paméla, Kazemi, Shirin, Friedmann, Jennifer E., Dionne, Jeanne, Cailhier, Jean-François, Bélanger, Karl, Ayoub, Jean-Pierre, Le, Huy, Lambert, Caroline, El-Hajjar, Jida, van Kempen, Léon C., Spatz, Alan, Miller, Wilson H.
Publicado no J Immunother Cancer (2017)